Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.

Key facts

Study ID

NCT01547299

Run by

Pfizer

People needed

52

Starts

2012-03-31

Expected to finish

2013-11-30

Last updated by the study team

2018-10-23

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Willing to provide informed consent
• 18 years of age or older
• Histologically confirmed adenocarcinoma of the prostate
• Must be a candidate for radical prostatectomy and considered surgically resectable

You may not qualify if…

• Stage T4 prostate cancer by clinical or radiologic evaluation
• Treatment with an investigational agent within 4 weeks prior to randomization
• Received therapy for other neoplastic disorders within 5 years
• Hypogonadism or severe androgen deficiency

Where it is running

• Study site — Boston, Massachusetts, United States
• Study site — Seattle, Washington, United States
• Study site — Vancouver, British Columbia, Canada
• Study site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.